Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk CEO defending GLP-1 pricing and the push to lower prices.

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

The new Lemme GLP-1 Daily Capsules are being called an "Ozempic alternative." But do they really work — and if so, at what ...

Novo Nordisk's CEO faced lawmakers in a grueling 2.5-hour hearing to discuss the cost of blockbuster drugs Ozempic and Wegovy ...

Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first ...

Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) are entero-pancreatic hormone-based treatments first approved in 2005 for type 2 diabetes (T2D). They are now commonly prescribed for weight ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...

The demand for weight loss medications are on the rise, and now, “natural” GLP-1s are being marketed to help you lose weight.